Showing 4261-4270 of 7593 results for "".
- Retin-A Micro Gel Microsphere 0.06% Now Available from Ortho Dermatologics to Treat Acnehttps://practicaldermatology.com/news/retin-a-micro-gel-microsphere-006-now-available-from-ortho-dermatologics-to-treat-acne/2457914/Retin-A Micro (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. The FDA approved Ortho Dermatologics' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgar
- Research Elucidates LIGHT's Role in ADhttps://practicaldermatology.com/news/research-elucidates-lights-role-in-ad/2457919/LIGHT, a member of the tumor necrosis factor (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis and other inflammatory skin diseases such as scleroderma, rep
- Adam Friedman, MD Wins Innovations in Residency Training Awardhttps://practicaldermatology.com/news/adam-friedman-md-wins-innovations-in-residency-training-award/2457920/The Journal of Drugs in Dermatology (JDD) awarded Adam Friedman, MD, FAAD with the Innovations in Residency Training Award at the recent Orlando Dermatology Aesthetic & Clinical Conference (ODAC) held in Miami. The award recognizes individuals who have fostered innovation and i
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv
- AAD Issues New Guidelines for Treatment of Non-melanoma Skin Cancerhttps://practicaldermatology.com/news/aad-issues-new-guidelines-for-treatment-of-non-melanoma-skin-cancer/2457928/The American Academy of Dermatology (AAD) has addressed the growing health concern about non-melanoma skin cancers (NMSC) with the release of its guidelines of care for the management of basal cell carcinoma and cutaneous squamous cell carcinoma, published online in the Journal of the Am
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte
- Jiangsu Hengrui Medicine and Arcutis Partner for Immune-Mediated Dermatology Therapy Using SHR0302https://practicaldermatology.com/news/jiangsu-hengrui-medicine-and-arcutis-partner-for-immune-mediated-dermatology-therapy-using-shr0302/2457936/Jiangsu Hengrui Medicine Co., Ltd., a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based in Menlo Park, CA, entered into an exclusive option and license agreement for the development and commercialization of topical applications of Hengr
- New AD Yardstick Highlights Treatment Advanceshttps://practicaldermatology.com/news/new-ad-yardstick-highlights-treatment-advances/2457933/Treatment for atopic dermatitis (AD) has changed a lot in the last few years, according to a new yardstick published in Annals of Allergy, Asthma and Immunology. “The Atopic Dermatitis Yardstick
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c